- Ticker
- ALBO
- Price
- -
- Stock movement down
- -0.10 (-0.23%)
- Company name
- Albireo Pharma Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 915.89M
- Ent value
- 914.56M
- Price/Sales
- 15.96
- Price/Book
- 9.15
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 60.14%
- 3 year return
- 22.16%
- 5 year return
- 5.49%
- 10 year return
- -5.96%
Last updated: 2023-05-17
Ipsen recognizes the huge potential of Albireo and is offering $42 plus a $10 CVR to acquire. Read more to see why I'm bullish on ALBO stock.
February 2, 2023
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Albireo Pharma, Inc. (ALBO) stock at Seeking Alpha.
January 11, 2023
iO Charts is a Seeking Alpha partner
DIVIDENDS
ALBO does not pay dividends or no data was received
Loading...
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 15.96 |
| Price to Book | 9.15 |
| EV to Sales | 15.94 |
Albireo Pharma entered into an agreement to get acquired by Ipsen. Bylvay is already approved for PFIC. Click for more on ALBO stock.
January 10, 2023
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Albireo Pharma, Inc. (ALBO) stock at Seeking Alpha.
January 9, 2023
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 20.74M |
| EPS (TTM) | -6.67 |
| FCF per share (TTM) | -9.63 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 57.39M |
| Gross profit (TTM) | 54.84M |
| Operating income (TTM) | -122.91M |
| Net income (TTM) | -131.15M |
| EPS (TTM) | -6.67 |
| EPS (1y forward) | -6.48 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 95.56% |
| Operating margin (TTM) | -214.16% |
| Profit margin (TTM) | -228.51% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 222.48M |
| Net receivables | 2.03M |
| Total current assets | 238.84M |
| Goodwill | 17.26M |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 321.22M |
| Accounts payable | 6.95M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 37.82M |
| Total liabilities | 221.15M |
| Shareholder's equity | 100.07M |
| Net tangible assets | 82.81M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -187.12M |
| Capital expenditures (TTM) | 2.16M |
| Free cash flow (TTM) | -189.28M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -131.05% |
| Return on Assets | -40.83% |
| Return on Invested Capital | -131.05% |
| Cash Return on Invested Capital | -189.15% |
Loading...
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| ALBO | S&P500 | |
| Current price drop from All-time high | -98.53% | -16.73% |
| Highest price drop | -99.77% | -56.47% |
| Date of highest drop | 17 Dec 2015 | 9 Mar 2009 |
| Avg drop from high | -90.07% | -11.49% |
| Avg time to new high | 265 days | 13 days |
| Max time to new high | 3811 days | 1805 days |
Albireo has one approved indication and one more filed for a label expansion. Find out what may present an opportunity to invest in ALBO in small proportions.
January 2, 2023
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Albireo Pharma, Inc. (ALBO) stock at Seeking Alpha.
December 19, 2022
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
915.89M
Marketcap category
Small-cap
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts. As of March 1, 2023, Albireo Pharma, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..
Employees
130
Investor relations
-
SEC filings
CEO
Ronald H. W. Cooper
Country
USA
City
Boston
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
Albireo Pharma, Inc. (NASDAQ:NASDAQ:ALBO) Q3 2022 Results Conference Call November 8, 2022 4:30 PM ETCompany ParticipantsHans Vitzthum - Managing Director, LifeSci AdvisorsRon Cooper -...
November 9, 2022
iO Charts is a Seeking Alpha partner
Get the latest news and real-time alerts from Albireo Pharma, Inc. (ALBO) stock at Seeking Alpha.
November 8, 2022
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
Get the latest news and real-time alerts from Albireo Pharma, Inc. (ALBO) stock at Seeking Alpha.
November 7, 2022
Sales for Bylvay's first approved indication is increasing. Albireo recently posted superb data for orphan disease known as Alagille Syndrome. Read more here.
October 12, 2022
Get the latest news and real-time alerts from Albireo Pharma, Inc. (ALBO) stock at Seeking Alpha.
October 11, 2022
Albireo Pharma is expanding Bylvay label for two other rare liver conditions, biliary atresia and Alagille syndrome. Read more about ALBO stock here.
October 3, 2022
Get the latest news and real-time alerts from Albireo Pharma, Inc. (ALBO) stock at Seeking Alpha.
September 22, 2022
Get the latest news and real-time alerts from Albireo Pharma, Inc. (ALBO) stock at Seeking Alpha.
September 6, 2022
Get the latest news and real-time alerts from Albireo Pharma, Inc. (ALBO) stock at Seeking Alpha.
August 16, 2022
Albireo Pharma, Inc. (NASDAQ:NASDAQ:ALBO) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ETCompany ParticipantsHans Vitzthum - LifeSci AdvisorsRon Cooper - CEO, President &...
August 16, 2022
Get the latest news and real-time alerts from Albireo Pharma, Inc. (ALBO) stock at Seeking Alpha.
August 15, 2022
Get the latest news and real-time alerts from Albireo Pharma, Inc. (ALBO) stock at Seeking Alpha.
August 12, 2022
iO Charts is a Seeking Alpha partnerNext page